AWARD NUMBER: W81XWH-19-1-0387

TITLE: Androgen Deprivation Therapy Resistance, Fatty Acid Oxidation, and the Role of Beta Hydroxybutyrate

PRINCIPAL INVESTIGATOR: Krizia Rohena Rivera

CONTRACTING ORGANIZATION: CEDARS-SINAI MEDICAL CENTER MATTHEW KIRK 8700 BEVERLY BLVD LOS ANGELES CA 90048-1804

REPORT DATE: October 2020

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Difference 10. SPONSOR/MONTOR'S ACCOMPAGE Difference 2. REPORT DATE ALTHE AND SUBTILE Annual ALTHE AND SUBTILE 3. DATES COVERED ALTHE AND SUBTILE 3. DATES COVERED ALTHE AND SUBTILE Annual ALTHE AND SUBTILE Annual Status 5. GRANT NUMBER ALTHE AND SUBTILE Annual Status 5. GRANT NUMBER	REPORT DOCUMENTATION PAGE					Form Approved OMB No. 0704-0188		
etc.best by Business of Business, Development of Protection Development of Protection Development Devel	Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the							
1. REPORT DATE: 2. REPORT TYPE: 3. DATES COVERED 4. TTLE AND SUBTILE Annual 15. EPT2019 - 31AUG2020 4. TTLE AND SUBTILE 5. CONTRACT NUMBER Androgen Deprivation Therapy Resistance, Faity Acid Oxidation, and the Role of Bata 5. GRANT NUMBER Microsybutyrate 5. CONTRACT NUMBER Willing and the Role of Bata 5. GRANT NUMBER Microsybutyrate 5. GRANT NUMBER State 1.9 - 1 - 0.337 5. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5. GRANT NUMBER Krizia Rohena Rivera 2316665 E-Mail: Krizia Rohena rivera @cshs.org 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 5. PERFORMING ORGANIZATION REPORT CLEARS - STAN MEDICIAL CENTER 8. PERFORMING ORGANIZATION REPORT MOTTEX KIEK 9.0048-1804 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. AMORELES CA. 90048-1804 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S ACRONYM(S) 13. SUPPLEMENTARY NOTES 11. SPONSOR/MONITOR'S ACRONYM(S) 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (AD1) (eg. abiraterone acotate and anzalutamide) is the standard systemic trainament hat promoso CPC as unot taken, ithe rode taket AD Corders a solution preasure Minithere	this burden to Department of I	Defense, Washington Headquart	ers Services, Directorate for Info	rmation Operations and Reports	(0704-0188), 1215 Jef	erson Davis Highway, Suite 1204, Arlington, VA 22202-		
October 2020 Innual 15EPT2019-31/31/02220 ArtTLE AND SOFTIET 5a. CONTRACT NUMBER Androgon Deprivation Therapy Resistance, Fatty Acid Oxidation, and the Role of Beta 5a. CONTRACT NUMBER Midrogon Deprivation Therapy Resistance, Fatty Acid Oxidation, and the Role of Beta 5a. CONTRACT NUMBER Will XXR = 19 - 10.337 5c. PROGRAM ELEMENT NUMBER 5c. PROGRAM LEMENT NUMBER CRDARDS Sci. PROJECT NUMBER 231665 FMail: Knzia.rohena-rivera@cshs.org Fill Work UNIT NUMBER Fill Work UNIT NUMBER F-Mail: Knzia.rohena-rivera@cshs.org Fill Work UNIT NUMBER Fill Work UNIT NUMBER F-Mail: Knzia.rohena-rivera@cshs.org Fill Work UNIT NUMBER Fill Work UNIT NUMBER F-Mail: Knzia.rohena-rivera@cshs.org Fill Work UNIT NUMBER Fill Work UNIT NUMBER F-Mail: Knzia.rohena-rivera@cshs.org Fill Work UNIT NUMBER Fill Work UNIT NUMBER TOB BUYSKIX BLWD Los ANOTORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Any Medical Research and Development Command Fill SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY				RESS.	3	DATES COVERED		
Androgen Deprivation Therapy Resistance, Fatty Acid Oxidation, and the Role of Beta B. GRANT NUMBER B. GRANT NUMBER B. GRANT NUMBER S. PROJECT NUMBER S. PROJECT NUMBER S. PROJECT NUMBER S. TASK NUMBER S. TASK NUMBER S. TASK NUMBER S. WORK UNIT NUMBER B. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) CDDMSP STUM MEDICAL CENTRER S. PONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command S. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command For Detrick, Maryland 21702-5012 I. SPONSOR/MONITOR'S REPORT NUMBER Supproved for Public Release; Distribution Unlimited Suprelease as asource of energy but there is angloring evento a signa	-				-			
Hydroxybuty'ate b. GRAM TUMBER #31X4T-19-1-0387 5c. PROGRAM ELEMENT NUMBER 8. AUTHOR(6) 6. AUTHOR(6) 6. AUTHOR(6) 6. AUTHOR(6) 7. PERFORMING ORGANIZATION NAME(6) AND ADDRESS(ES) 7. SPONSORING / MONITORING AGENCY NAME(6) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(5) 11. SPONSOR/MONITOR'S ACRONYM(5) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen depivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially affactive, within 2-3 years of treatment, most patients will develop caratration resistant prostate cancer (CPCa), androgen depivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially affactive, within 2-3 years of treatment, most patients will develop caratration resistant prostate cancer (CPCa), Although mechanisms that promote CRCP care uncertain, it is noted that ADT corlers a selective pressure. White most research has focused on PCa epiblelia.our lab has shown that there is a selective pressure over the surrounding strome as well. In essence, these floxibility to compare the surrounding strome as well in the order of th	4. TITLE AND SUBTIT	rle .			5a	CONTRACT NUMBER		
AUTHOR(S) Krizia Rohena Rivera Composition of the second se		n Therapy Resistance,	Fatty Acid Oxidation, a	and the Role of Beta				
6. AUTHOR(6) Sc. PROGRAM ELEMENT NUMBER 6. AUTHOR(6) Sc. PROGRAM ELEMENT NUMBER 7. PERFORMING ORGANIZATION NAME(6) AND ADDRESS(ES) St. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(6) AND ADDRESS(ES) St. PERFORMING ORGANIZATION REPORT MATTHER KIR St. PONSORING / MONITORING AGENCY NAME(6) AND ADDRESS(ES) St. PERFORMING ORGANIZATION REPORT 1.05 ANGELES C.A. 90048-1804 SPONSORING / MONITORING AGENCY NAME(6) AND ADDRESS(ES) I.S. SPONSOR/MONITOR'S AGENCY NAME(6) AND ADDRESS(ES) U.S. Army Medical Research and Development Command To. SPONSOR/MONITOR'S REPORT Fort Detrick, Maryland 21702-5012 To. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES Torefars a selective pressure. While most resistant protect C(CPC). Although mechanisms this robreads on FGA ango and entrophysical resource of neighborhous resistant protect C(CPC). Although mechanisms that promote CRF care uncertain, it is tored that ADT corlers a selective pressure. While most research has focubed on PCA ango and protect pressure. While most research has focubed on PCA ango ango source of ency (CPC). Although mechanisms that promote CRF care presender. While most research has focubed on PCA ango and proved on FLA ango and as well. In essence, these discludes the beach integrate and enzewhere bookes his beach and the respondent of the surgeounding stroma as well. In essence, these discludes the beach andre averse contex sele	Trydroxybatyrate							
Krizia Rohena Rivera 23165 E-Mail: krizia rohena-rivera@cshs.org 5. WORK UNIT NUMBER E-Mail: krizia rohena-rivera@cshs.org 5. WORK UNIT NUMBER 2.7.PERFORMING GRGANIZATION RAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT WATTHAW KLINK 9. DESTROATING ORGANIZATION RAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT S. ANSELES CA 90048-1804 10. SPONSORIMONITOR'S ACCONYM(S) 10. SPONSORIMONITOR'S ACCONYM(S) U.S. Army Medical Research and Development Command 11. SPONSORIMONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSORIMONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (ag. abbraterone acetate and analutanide) is the standard systemic treatment, mort palate and will develop control in testand prostate concer (CPC2). Altodyn prostate concer (CPC2), androgen deprivation therapy (ADT) (ag. abbraterone acetate and analutanide). Is the standard systemic treatment, mort palate and will develop control in testand prostate concer (CPC2). Altodyn prostate concer (CPC3). Antodyn prostate concer (CPC2). Altodyn prostate concer (CPC3). Antodyn prostate concer (CPC3). Antodyn prostate concer (CPC3). Antodyn prostate concer (CPC3). Antodyn prostate concer (CPC2). Altodyn prostate concer (CPC3). Antodyn prostate concochin (LPC3). Altodyn prostate concer (CPC3). Antodyn pr								
Krizia Rohena Rivera 23165 E-Mail: krizia rohena-rivera@cshs.org 5. WORK UNIT NUMBER E-Mail: krizia rohena-rivera@cshs.org 5. WORK UNIT NUMBER 2.7.PERFORMING GRGANIZATION RAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT WATTHAW KLINK 9. DESTROATING ORGANIZATION RAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT S. ANSELES CA 90048-1804 10. SPONSORIMONITOR'S ACCONYM(S) 10. SPONSORIMONITOR'S ACCONYM(S) U.S. Army Medical Research and Development Command 11. SPONSORIMONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSORIMONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (ag. abbraterone acetate and analutanide) is the standard systemic treatment, mort palate and will develop control in testand prostate concer (CPC2). Altodyn prostate concer (CPC2), androgen deprivation therapy (ADT) (ag. abbraterone acetate and analutanide). Is the standard systemic treatment, mort palate and will develop control in testand prostate concer (CPC2). Altodyn prostate concer (CPC3). Antodyn prostate concer (CPC2). Altodyn prostate concer (CPC3). Antodyn prostate concer (CPC3). Antodyn prostate concer (CPC3). Antodyn prostate concer (CPC3). Antodyn prostate concer (CPC2). Altodyn prostate concer (CPC3). Antodyn prostate concochin (LPC3). Altodyn prostate concer (CPC3). Antodyn pr								
E-Mail: krizia rohena-rivera@cshs.org 56. TASK NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 51. WORK UNIT NUMBER CEDARS-SINAI I MEDICAL CENTER MUTHIEW KIRK 8700 BEVERLY BUD 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORIMONITOR'S ACRONYM(S) U.S. Army Medical Research and Development Command 11. SPONSORMONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment, Mithough initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure over the surrounding stroma as well. In essence, these flooblasts co-evole to support timor growth under adverse conditions, Regulation of fatty acid oxidation (FAO)has been identified as a mignal synometed. KAtone bodies like bestandard systemic treatment. Miter Bio a selective pressure over the surrounding stroma as well in essence, these flooblasts co-evole to support timor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a mignal monout as bioms that ADT confers a selective pressure. While most shate for concert with the biosevel to have an important pharmacological role in cancer, we sought to investigate the role of HBD contains when exposed to ADT, while is utilization by adjacent epithelia an eachyme investige the role								
E-Mail: krizia.rohena-rivera@cshs.org St. WORK UNIT NUMBER 7. PERFORMING GRANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT CEDARS-SINAT MEDICACL CENTER NUMBER MITTIBUE KITR 8. PERFORMING ORGANIZATION REPORT S700 BEVERLY BLVD LOS ANGELES CA 90048-1804 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Development Command 11. SPONSOR/MONITOR'S ACRONYM(S) 12. SATTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Athough Initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Athough mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most source to energy in PCa. In fact, chinal stashown that there is a selective pressure of the structure is an electribulation and source to energy in PCa. In fact, chinal stashown that ergymes noved in the ktologe patients will develop castration resistant prostate cancer (CRPC). Athough mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most source of energy in PCa. In fact, chinal stashown that there is a selective pressure of the structure is a selective pressure. While most source of energy in PCa. In fact, chinal stashown that there is a selective pressure. Therefore, the protosite ca	Krizia Rohena Rivera							
E-Mail: ktizia nohena-rivera @csh.ord 7.PEPGORUMIG OGGANIZATION NAME(S) AND ADDRESS(ES) NUMBER WATTHEW XIMEDICAL CENTER NUMBER WATTHEW XIMEDICAL CENTER NUMBER S.PONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Development Command 11. SPONSOR/MONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT How Service Common Servi					Se	TASK NUMBER		
7. PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) (EDARAS-STINAL MEDICAL CENTER MATTHEW KIRK 8700 BEVENLY BLVD LOS ANGELES CA 90048-1804 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$) 10. SPONSOR/MONITOR'S ACRONYM(\$) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(\$) 12. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT NUMBER(\$) 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRC are uncertain, it is noted that DT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stoma as well. In sesten throstate cancer (CRPC), Although mechanisms that promote CRCPC are uncertain, it is noted that DT confers a selective pression. Interestingly, we found that ketone body production was increased in Inforbalasts when exopaced to ADT, while its illization by adjacent epithelia our also instructed in Inforbalasts when exopaced to ADT, while its illization by adjacent epithelia in astinal molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHG in serving CRPC by clauding the role of FAO. Inholocule interaction. ERC by studying the role of FAO. Inholeculae in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BH					5f.	WORK UNIT NUMBER		
CEDARS-STNAT MEDICAL CENTER NUMBER 8700 BEVERLY BLVD LOS ANGELES CA 90048-1804 10. SPONSORIMG / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Development Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT MUMBER(S) 11. SPONSOR/MONITOR'S REPORT 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg, abiraterone acetate and enzalutamide) is the standard systemic treatment, Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC), Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has floxlasts co-neer (CRPC), Although midally effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC), Although midally effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC), Although midally effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC), Although moder adverse conditions. Regulation of fatty add oxidation (FAC) has been diveloped. PCa In fact, clinical studies have shown that there is a selective pressure. While most research has floxlasts co-nored (CRPC), PCa. In fact, clinical studies have shown that anymes involved in the ketogenic pathway are increased in PCa pagesion. Interestingly, we found that ketone body production was increased in Inprotater paramacasion a signaling molecule. HDAC inhibitor	E-Mail: krizia.rohe	ena-rivera@cshs.or	g					
MATTHEW KIRK B700 BEVERLY BLVD LOS ANGELES CA 90048-1804 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) J.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CPC). Although mechanisms that promote CPC are uncertain, it is noted that ADT confre as abelective pressure. While most research has focused on PCa epithelia.our lab has shown that there is a selective pressure over the surrounding stroma as well. messence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatts, to its utilization by adjacent epithelia was promoted. Ketone bodies like beta- hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifies literation was increased in fibroblasts when exposed to ADT, while the IAT Promites CRPC phenotype. Blockade of taking and that borned evelop thereas in the is ongoing evidence of its importance as estimate the role of FAO in atoma epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of taking and metabolism in stoma can sensitize PCa epithelia lite test on this modulatin through ADT promotes CRPC phenotype. Blocka			AND ADDRESS(ES)		-			
8700 BEVERLY BLVD LOS ANGELES CA 90048-1804 I 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although Initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia.our lab has shown that there is a selective pressure over the surrounding stroma as well. Incessnee, these floroblasts co-evolve to support tumor growth under adverse conditions. Regulation of tatly add oxidation (FAO) has been identified as a major source of energy in PCa. In text, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in hittohlast when exposed to ADT, while is utilization by adjacent epithelia was promoted. CAPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the doserved elevated BHB can have a important pharmacological to in cancer, we sought to investigate the role of LAPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the doserved elevated BHB in extrans a signaling m		MEDICAL CENTER				NOMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 yaes of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia.our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, hese fibroblasts co-evolve to support tumor growth under adverse conflorms. Regulation of fatty acid oxidation (FAC)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that there is a selective pressure over the surrounding stroma as well. In essence, hese fibroblasts co-evolve to support tumor growth under adverse conflorms. Regulation of fatty acid oxidation (FAC)has been identified as a major source of energy in PCa. In fact, clinical studies tabees shown that Ton non-responsive patients have lower levels of BHB in serum which was in concert with the besten- bydroxyburytet (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule. HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our las shows that ADT		BLVD						
U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epihelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibrolasts co-evolve to support tumor growth under adverse conditions. Regulation of fatly acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that there is a selective pressure over the surrounding strome as well. In essence, these fibrolasts co-evolve to support tumor growth under adverse conditions. Regulation of fatly acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that there is a super source of the surrounding strome as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB is nervue which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promoted. Ketone bodies like beta- hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of	LOS ANGELES CA	A 90048-1804						
U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epihelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibrolasts co-evolve to support tumor growth under adverse conditions. Regulation of fatly acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that there is a selective pressure over the surrounding strome as well. In essence, these fibrolasts co-evolve to support tumor growth under adverse conditions. Regulation of fatly acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that there is a super source of the surrounding strome as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB is nervue which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promoted. Ketone bodies like beta- hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of								
U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epihelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibrolasts co-evolve to support tumor growth under adverse conditions. Regulation of fatly acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that there is a selective pressure over the surrounding strome as well. In essence, these fibrolasts co-evolve to support tumor growth under adverse conditions. Regulation of fatly acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that there is a super source of the surrounding strome as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB is nervue which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promoted. Ketone bodies like beta- hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of				0/50)				
Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. Nessence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in approxematic as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB unitset by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia and the cancer of PABS in Stract 16. SECURITY CLASSIF	9. SPONSORING / MC		AME(5) AND ADDRES	5(ES)	10	SPONSOR/MONITOR'S ACRONTM(S)		
Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. Nessence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in approxematic as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB unitset by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia and the cancer of PABS in Stract 16. SECURITY CLASSIF	U.S. Army Medical Research and Development Command							
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that extremes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketorne body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signal gmolecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Predipties and the tAD non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC Pet phonephe. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzelutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction.					11.	SPONSOR/MONITOR'S REPORT		
Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAQ)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia aves promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid elevated BHB utilization by epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT	-					NUMBER(S)		
Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAQ)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia aves promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid elevated BHB utilization by epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT								
13. SUPPLEMENTARY NOTES 14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSI	12. DISTRIBUTION / AVAILABILITY STATEMENT							
14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17.	Approved for Publ	lic Release; Distribu	ition Unlimited					
14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17.								
14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eg. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS 16. SECURITY CLASSIFICATION OF: 16. SECURITY CLASSIFICATION OF: 17.								
treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by apithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia clels to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE Unclassified	13. SUPPLEMENTARY NOTES							
treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by apithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia clels to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE Unclassified								
treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although mechanisms that promote CRPC are uncertain, it is noted that ADT confers a selective pressure. While most research has focused on PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by apithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia clels to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE Unclassified	14. ABSTRACT For prostate cancer (PCa), androgen deprivation therapy (ADT) (eq. abiraterone acetate and enzalutamide) is the standard systemic							
epithelia, our lab has shown that there is a selective pressure over the surrounding strom a swell. In essence, these fibroblasts co-evolve to support tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta- hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelia cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION 0 F ABSTRACT 18. NUMBER 0 F PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRDC 19b. TELEPHONE NUMBER <i>(include area</i> <i>code)</i>	treatment. Although initially effective, within 2-3 years of treatment, most patients will develop castration resistant prostate cancer (CRPC). Although							
tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact, clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: a. REPORT b. ABSTRACT c. THIS PAGE Unclassified Unclassified Unclassified Unclassified Unclassified								
body production was increased in fibroblasts when exposed to ADT, while its utilization by adjacent epithelia was promoted. Ketone bodies like beta- hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION of ABSTRACT 18. NUMBER 0F PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRDC 19b. TELEPHONE NUMBER <i>(include area</i> <i>code)</i>	tumor growth under adverse conditions. Regulation of fatty acid oxidation (FAO)has been identified as a major source of energy in PCa. In fact,							
hydroxybutyrate (BHB) serve as a source of energy but there is ongoing evidence of its importance as a signaling molecule, HDAC inhibitor and histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT b. ABSTRACT c. THIS PAGE Unclassified Unclassified	clinical studies have shown that enzymes involved in the ketogenic pathway are increased in PCa progression. Interestingly, we found that ketone							
histone modifier. Given that BHB can have an important pharmacological role in cancer, we sought to investigate the role of this molecule in CRPC. Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: a. REPORT Unclassified Unclassified Unclassified Unclassified Unclassified b. ABSTRACT c. THIS PAGE Unclassified b. ABSTRACT c. THIS PAGE c. THIS PAGE f. C. THI								
Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed elevated BHB utilization by epithelia in culture. Therefore, we hypothesize that FAO modulation through ADT promotes CRPC phenotype. Blockade of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 19a. NAME OF RESPONSIBLE PERSON USAMRDC a. REPORT b. ABSTRACT c. THIS PAGE Unclassified 9 Unclassified Unclassified 9 19b. TELEPHONE NUMBER (include area code)								
of fatty acid metabolism in stroma can sensitize PCa epithelial cells to enzalutamide. Our broad objective is to elucidate mechanisms that promote CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRDC a. REPORT b. ABSTRACT c. THIS PAGE Unclassified 19b. TELEPHONE NUMBER (include area code) Unclassified Unclassified 9 19b. TELEPHONE NUMBER (include area code)	Preliminary data from our lab shows that ADT non-responsive patients have lower levels of BHB in serum which was in concert with the observed							
CRPC by studying the role of FAO in stromal-epithelia interaction. 15. SUBJECT TERMS NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRDC a. REPORT b. ABSTRACT c. THIS PAGE 19a. NAME OF RESPONSIBLE PERSON USAMRDC Unclassified Unclassified 9 19b. TELEPHONE NUMBER (include area code)								
NONE LISTED 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRDC a. REPORT b. ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area code) Unclassified Unclassified 9								
16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRDC a. REPORT b. ABSTRACT c. THIS PAGE Unclassified 19b. TELEPHONE NUMBER (include area code) Unclassified Unclassified 9 Code)								
a. REPORT b. ABSTRACT c. THIS PAGE OF ABSTRACT OF PAGES USAMRDC unclassified Unclassified Unclassified 9 19b. TELEPHONE NUMBER (include area code)	NONE LISTED							
a. REPORT b. ABSTRACT c. THIS PAGE Unclassified Unclassified Unclassified Unclassified 09	16. SECURITY CLAS	SIFICATION OF:						
Unclassified Unclassified Unclassified 9 code)	a. REPORT	b. ABSTRACT	c. THIS PAGE	OF ADOLKAUL	OF FAGES			
Unclassified Unclassified Unclassified				Unclassified	9			
	Unclassified	Unclassified	Unclassified			Standard Form 298 (Rev. 8-98)		

Prescribed by ANSI Std. Z39.18

TABLE OF CONTENTS

Pages

1.	Introduction	1
2.	Keywords	1
3.	Accomplishments	1-4
4.	Impact	4-5
5.	Changes/Problems	5
6.	Products	5
7.	Participants & Other Collaborating Organizations	5
8.	Special Reporting Requirements	5
9.	Appendices	5

Introduction

PCa is the most commonly diagnosed non-cutaneous type of cancer, and the second leading cause of death (1). Androgen signaling deprivation therapy (ADT) (e.g. abiraterone acetate and enzalutamide) is the standard systemic treatment. Although ADT is initially effective, within 2-3 years of treatment, most men will progress towards castration resistance (CRPC). Unfortunately, management for metastatic CRPC involves adjuvant therapy with taxane-derivative drugs (e.g. docetaxel) with poor subsequent survival (2,3). It is noted that ADT therapy confers a selective pressure that changes the epithelial cells. Some changes include, androgen receptor (AR) reactivation via over expression, enzyme up-regulation and the expression of aberrant splice variants (4). Although most research has focused PCa epithelia, our lab has shown that there is a selective pressure over the surrounding stroma as well. In essence, fibroblasts co-evolve to support tumor growth under adverse conditions like ADT or nutrient deprivation (5). Data from our lab shows a genetic signature that can differentiate tumor-inductive stroma (cancer associated fibroblasts; CAF) - and non-tumor inductive stroma (normal associated fibroblasts; NAF) (6). In addition, we show that fibroblast exposure to ADT (e.g. castration, abiraterone, enzalutamide) promotes a CAF-like genetic signature. Regulation of fatty acid oxidation (FAO) has been identified as a hallmark of cancer. For PCa epithelia, unlike many other Warburg (glycolysis-dependent) cancers, FAO is a major source of energy. Moreover, there is clinical evidence that enzymes involved in the ketogenic pathway are increased in PCa progression (7). Ketone bodies like beta-hydroxybutyrate (BHB) serve as a source of energy during starvation. In addition to being a substrate for metabolic breakdown, BHB is also a recognized signaling molecule, HDAC inhibitor, and histone modifier (8,9). Given the growing evidence that BHB can have multiple roles in cancer, we sought to investigate its impact in CRPC.

Keywords

Prostate cancer, cancer-associated fibroblasts, neuroendocrine differentiation, enzalutamide, castrationresistant prostate cancer, androgen deprivation therapy, fatty acid metabolism, ketone body metabolism, beta hydroxy butyrate

Accomplishments

Major goals of the project as stated in the approved SOW

Major Goal 1: Metabolic characterization of NAF and CAF

Major Goal 2: Metabolic profiling of stromal cells when exposed to ADT

Major Goal 3: To define the role of BHB in CRPC

Aim 1. To delineate the role of fatty acid oxidation in NAF and CAF.

Aim 1A. Metabolic characterization of NAF and CAF.

Major Activities: To understand the metabolic characteristics of patient derived NAF and CAF we evaluated the expression of ketone body metabolism genes 3-Hydroxybutyrate Dehydrogenase 1 (BDH1), which catalyzes the reversible conversion between acetoacetate and beta-hydroxy butyrate (BHB), and 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 (HMGCS2) which catalyzes the rate limiting step. **Specific objectives**: To mimic stress conditions of the tumor microenvironment, we exposed cells to normoxia or hypoxia for 72 hours. **Key Outcomes:** We observed that in hypoxic conditions, CAF have higher expression of HMGCS2. In NAF however, we observed that HMGCS2 expression was negligible in hypoxic conditions. This result suggests that BHB production is promoted in CAF during stress. BDH1 expression was dramatically reduced in NAF during hypoxia while in CAF it remained unchanged (Figure 1).



Figure 1: Real-Time PCR results of BDH1 and HMGCS2 expression in NAF and CAF. Fold change calculated using the Ct method relative to NAF under normoxia.

Aim 1B. Interrogate the impact of stromal ketogenesis on epithelia.



affects tumor development. Prostate orthotopic grafts were allowed to grow into tumors for 4 weeks, tumor volume was determined with caliper measurements. FFPE tissues were used for H&E, PH3, CHGA and HMGCS2 staining. Results suggest that HMGCS2KO fibroblasts do not support tumor growth as well as WT fibroblasts.



Figure 3: Changes in fatty acid oxidation induced by Enzalutamide. Murine fibroblasts were exposed to 10uM Enzalutamide for 72h in both normoxia and hypoxia. The expression of genes in volved in fatty acid oxidation are significantly increased.

Specific objectives: To further understand the effect of ketogenesis in tumor growth we performed an *in vivo* experiment. We utilized orthotopic grafting of 22RV1 with either WT murine fibroblasts or HMGCS2 KO fibroblasts. **Key Outcomes:** Our findings, although not significant, show a trend that WT fibroblasts are able sustain to tumor growth better than HMGCS2 KO fibroblasts. Moreover, we observed the same trend with phosphorylated histone H3 (PH3) and chromogranin A (CHGA) (Figure 2).

Aim 1C. Determine if ketogenic differences in PCa patients predict biochemical recurrence following prostatectomy.

Subtask 4: Statistical analysis BHB and Biochemical recurrence

Nothing to report

Aim 2. To determine the action of BHB in CRPC.

Major Goal 2: Metabolic profiling of stromal cells when exposed to ADT

Subtask 1: Seahorse XF OCR and ECAR for stromal cells exposed to ADT

Subtask 2: Generate HMGCS2KO Stromal cells

Aim 2A. Metabolic reprogramming of stromal fibroblasts induced by ADT

Major Activities: To study the effects of ADT in stromal metabolic reprogramming, we exposed murine prostate fibroblasts to enzalutamide for 72h in normoxic and hypoxic conditions. **Key Outcomes:** Our results showed that regardless of oxygen levels, enzalutamide was able to increase the expression of CPT1, CPT2 and HMGCS2 suggesting higher fatty acid oxidation and ketone body production. To discard if ketone body production could cause epigenetic changes, we

evaluated Sirtuin 1 (SIRT1) which is a commonly known cell regulator involved in histone deacetylation. However, we did not observe any significant changes. Afterwards, we evaluated mitochondrial turnover using fibroblasts expressing MitoTimer. This tool is a mitochondrial tagged reporter protein (dsRed) which shifts from green to red as it oxidizes. Key Outcomes: Our data showed that exposure to enzalutamide enhanced mitochondrial biogenesis, in addition we verified that PGC1a expression was increased using qPCR. Looking at oxygen consumption rate (OCR) using Seahorse we found that overall fibroblasts exposed to enzalutamide have more active mitochondria, we paired this result to the higher expression of CPT1 by qPCR. In addition to this data we looked at the expression of the enzymes involved in ketone body synthesis HMGCS2 and BDH1 and just as we saw with CAF under hypoxia, expression of both these genes was increased. Finally, we evaluated the expression of a curated CAF signature panel we have in our lab. We observed that the majority of these were increased, establishing that exposure to enzalutamide can reprogram murine fibroblasts to express more CAF-like characteristics (Figure 4).



Figure 4: Stromal metabolic changes under ADT. In all cases murine prostatic stroma was cultured to 70% confluency and exposed to enza for 72h. A) MitoTimer stroma shows increased mitochondrial turnover (green) when exposed to enza. B) Seahorse experiment shows that enza increased basal respiration, spare respiratory capacity, proton leak and ATP production. C) qPCR results show increased PGC1a, CPT1, HMGCS2 and BDH1. *P < 0.05, **P < 0.01, ****P < 0.0001 D) Expression of curated CAF markers was measured using qPCR and analyzed using the CT method. Fold change is represented in heat map form.

Aim 2B. To define the role of BHB in CRPC.



cell growth and response to ADT A) R-BHB and S-BHB chemical structure. B) 22Rv1 cells were exposed to R or S-BHB for 72 hours in the context of enza 5uM. Growth was significantly reduced with S-BHB while R-BHB rescued survival. *P<0.05, **P<0.01, ***P<0.0001. **Major Activities:** To study the effect of BHB in epithelia we first focused on the effects of BHB itself. Given that BHB is a chiral molecule, we took advantage that S-BHB is not readily metabolized but exerts all signaling functions to look at a scenario where BHB is not consumed. **Specific objectives:** For these experiments we cultured 22Rv1 cells with either R-BHB and S-BHB (5mM) and treated them for 72h with Enzalutamide (5uM). **Key Outcomes:** Our results showed that S-BHB was able to increase cell death by Enzalutamide while R-BHB was able to promote survival (Figure 5). This result suggests that S-BHB may have pharmacological value..

Opportunities for training and professional development

The specific goals of this project have increased my knowledge in the use of CRISPR and had raised the opportunity to train other laboratory members in this technique. I have attended scientific meetings like the SBUR which are focused on urologic cancers to share my findings. In addition, with my mentors, we actively discuss career goals and future endeavors in weekly metings.

How were the results disseminated to communities of interest?

These results have been shared in the SBUR meeting as a poster presentation.

What do you plan to do during the next reporting period to accomplish the goals?

During next reporting period we will focus on completing the following goals as approved in the SOW

Major Goal 1: Metabolic characterization of NAF and CAF

Subtask 4: Statistical analysis BHB and Biochemical recurrence

Major Goal 2: Metabolic profiling of stromal cells when exposed to ADT

Subtask 3: Determine ketone body production

Major Goal 3: To define the role of BHB in CRPC

Subtask 1: Generate OXCT1KO PCa cells Subtask 2: Tissue recombination experiments Subtask 3: Mouse model, tissue processing and staining

Impact:

What was the impact on the development of the principal discipline(s) of the project?

Our results for the metabolic behavior of NAF and CAF bring more light into the stromal component of the tumor microenvironment and their role in shaping response to therapy. Specifically, metabolic enzymes can be novel targets to improve current therapy and prevent resistance.

What was the impact on other disciplines?

Our findings surrounding the study of ketone body metabolism and thinking of these enzymes as possible targets can expand into other disciplines outside of prostate cancer and currently, we are working on exploring these aspects in other cancer models.

What was the impact on technology transfer?

Nothing to report.

What was the impact on society beyond science and technology?

Nothing to report.

Changes/Problems

Major Goal 1: Metabolic characterization of NAF and CAF

Subtask 1: Seahorse XF OCR and ECAR for NAF and CAF Subtask 2: Determine ketone body production in NAF and CAF Subtask 3: Generate HMGCS2KO stromal cells

Due to the extensive variability between patient derived NAF and CAF, to complete Aim 1A we have decided to employ the use of murine-derived fibroblasts specifically for the seahorse experiments. We have shown that murine fibroblasts do express a CAF-like genetic signature with prolonged exposure to enzalutamide, therefore we have done experiments between naïve fibroblasts and those with a consistent exposure to enzalutamide. In addition, we will employ the use of CRISPR Cas9 technology solely on murine derived fibroblasts and not NAF and CAF. Moreover, we have seen advances in CRISPR Cas9 technology since the submission of this proposal. Hence, we changed our system from a double plasmid method to a single plasmid method (Lentiviral CRISPRV2 plasmid) which reduces cell selection time and has higher success rate (10).

Major Goal 3: To define the role of BHB in CRPC

Subtask 1: Generate OXCT1KO PCa cells Subtask 2: Tissue recombination experiments

The Covid-19 pandemic caused a delay for in vivo experiments and hands-on work. The generation of OXCT1 epithelial knock outs on 22RV1 was significantly affected, however the project continues as planned. In addition, for the experiments involving co-culture, we have decided to employ the use of boyden chambers instead of the collagen mixture. Our rationale for such change relies on making our results specific to the activity of small molecules instead of cell interactions. Additionally, this method reduces the amount of cell death resulting from the collagen digestion and cell sorting procedure.

Products

Presentations:

Poster Presentation

Role of beta hydroxybutyrate in androgen receptor signaling inhibition therapy resistance. SBUR 2018 Annual Meeting Precision Medicine in Urology: Molecular Mechanisms, Diagnostics and Therapeutic Targets November 8-11, 2018 Rancho Mirage, CA

Participants & Other Collaborating Organizations

Name:	Krizia Rohena Rivera
Project Role:	Principal investigator
ORCID ID:	0000-0003-3391-8742
Months Worked:	12
Contribution:	Performing experiments, data analysis, data report.
Name:	Ashley Heard
Project Role:	Laboratory technician
ORCID ID:	Not registered
Months Worked:	7
Contribution:	Technical assistance with experiments.

Special Reporting Requirements

Nothing to report

Appendices Nothing to report

References:

- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan 5;65(1):5–29.
- Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002 May;2(5):389– 96.
- 3. Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat Rev. 2015 Jul;41(7):588–97.
- 4. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759–65.
- 5. Banerjee J, Mishra R, Li X, Jackson RS, Sharma A, Bhowmick NA, et al. A reciprocal role of prostate cancer on stromal DNA damage. Oncogene. 2014 Oct 9;33(41):4924–31.
- 6. Kato M, Placencio-Hickok VR, Madhav A, Haldar S, Tripathi M, Billet S, et al. Heterogeneous cancerassociated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene. 38(5).
- 7. Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, et al. Quantitative Proteomics

Reveals That Enzymes of the Ketogenic Pathway Are Associated with Prostate Cancer Progression. Mol Cell Proteomics. 2013 Jun 1;12(6):1589–601.

- 8. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25(1):42–52.
- 9. Xie Z, Zhang D, Chung D, Tang Z, Huang H, Dai L, et al. Metabolic Regulation of Gene Expression by Histone Lysine β-Hydroxybutyrylation. Mol Cell. 2016 Apr 21;62(2):194–206.
- 10. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Vol. 11, Nature Methods. Nature Publishing Group; 2014. p. 783–4.